康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 09-17 16:08:09

90.750

+0.350

+0.39%

最高92.200	最低90.300	成交量499.59万
今开91.000	昨收90.400	日振幅2.10%
总市值835.81亿	流通市值835.81亿	总股本9.21亿
成交额4.55亿	换手率0.54%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":90.75,"timestamp":1789632489008,"preClose":90.4,"halted":0,"volume":4995881,"delay":0,"changeRate":0.0038716814159291406,"floatShares":921000000,"shares":921000000,"eps":-1.4428255911590937,"marketStatus":"未开盘","change":0.35,"latestTime":"09-17 16:08:09","open":91,"high":92.2,"low":90.3,"amount":455282170,"amplitude":0.021018,"askPrice":90.75,"askSize":70000,"bidPrice":90.7,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-1.2376616864255843,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789695000000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":90.4,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"volumeRatio":0.4466250904512561,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.5703,"impliedVolPercentile":0.3232},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2668959205","title":"康方生物迎大敌：荣昌生物RC148亮相世界肺癌大会 预计峰值销售额约36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959205","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668959205?lang=zh_cn&edition=full","pubTime":"2026-09-17 14:17","pubTimestamp":1789625820,"startTime":"0","endTime":"0","summary":"9月15日，荣昌生物与艾伯维联合开发的PD-1/VEGF双抗RC148一线治疗鳞状和非鳞状非小细胞肺癌的II期临床数据以口头报告形式在世界肺癌大会亮相。基于以上参数计算，RC148 大中华区峰值年销售额约为 36 亿元。从时间维度来看，RC148 预计 2030 年左右获批上市，通常创新药上市后需经历 5-7 年的市场爬坡期达到销售峰值，预计 2036 年左右达到峰值销售额，距离当前时点约 10 年。结合 0.50 的临床成功概率，最终 RC148 大中华区管线的风险调整净现值约为 5.6 亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-17/doc-iniscksf0292708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","IE00B543WZ88.USD","LU2778985437.USD","KURE","BK1574","LU2476274720.SGD","LU0417516571.SGD","LU0417516738.SGD","LU0634319403.HKD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348827113.USD","LU1969619763.USD","LU0348783233.USD","LU2399975544.HKD","LU2328871848.SGD","LU0348825331.USD","LU0348784397.USD","09926","LU1720050803.USD","LU0348735423.USD","LU2148510915.USD","LU2476274308.USD","LU1064131003.USD","BK1583","LU1794554557.SGD","LU2488822045.USD","LU1961090484.USD","LU0348766576.USD","09995","BK1161","BK0239","LU0417516902.SGD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0561508036.HKD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668959410","title":"中金：上调康方生物(09926)目标价8.3%至130港元 维持“跑赢行业“评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959410","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668959410?lang=zh_cn&edition=full","pubTime":"2026-09-17 14:08","pubTimestamp":1789625310,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，康方生物公告AK112，商品名为依达方，对比帕博利珠单抗用于一线治疗PD-L1阳性NSCLC的注册性III期临床于WCLC公布OS显著阳性结果。考虑到H2数据亮眼，该行上调海外H7临床成功概率，维持2026年和2027年盈利预测不变，维持\"跑赢行业\"评级，上调目标价8.3%至130港元。目前，AK112对比帕博利珠单抗一线治疗PD-L1阳性NSCLC的国际多中心III期临床研究正在持续入组中，该行认为该临床未来胜出概率较大。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","EWH","HELS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668956446","title":"研报掘金丨中金：上调康方生物目标价至130港元，维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2668956446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668956446?lang=zh_cn&edition=full","pubTime":"2026-09-17 13:36","pubTimestamp":1789623377,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0417516571.SGD","LU0348766576.USD","LU2488822045.USD","LU0348825331.USD","BK1161","LU2399975544.HKD","LU1720050803.USD","LU0348783233.USD","LU0634319403.HKD","LU0417516902.SGD","KURE","LU0417516738.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348827113.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU1961090484.USD","09926","LU2476274308.USD","LU0540923850.HKD","LU2476274720.SGD","LU0561508036.HKD","LU0348767384.USD","IE00B543WZ88.USD","LU0348784397.USD","LU2778985437.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125173008","title":"异动解读｜康方生物盘中下跌3.04%，WCLC利好数据兑现后资金获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1125173008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125173008?lang=zh_cn&edition=full","pubTime":"2026-09-16 09:33","pubTimestamp":1789522436,"startTime":"0","endTime":"0","summary":"9月16日，康方生物盘中下跌3.04%，报92.35港元/股，成交额6568.64万港元。该利好已于9月14日推动股价上涨逾5%，9月15日卖空占比高达33.18%，显示利好充分消化后部分资金选择获利了结。此外，公司此前披露的中期业绩显示收入及毛利不及部分机构预期，亦对短期情绪形成压制。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物高位回落，获利盘了结施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648612","title":"可以多活8.2个月！国产双抗挑战全球肿瘤“药王”总生存期胜出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667648612?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:46","pubTimestamp":1789461960,"startTime":"0","endTime":"0","summary":"2026年世界肺癌大会，对于国产创新药而言，不只是“被看见”，更要回答一个硬核的问题：到底能不能让患者活得更久。继翰森制药ADC药物刷新全球小细胞肺癌二线治疗最长总生存期（OS）纪录外，另外一款国产创新药挑战全球肿瘤“药王”总生存期的数据也揭晓了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874734252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874734252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","LU2488822045.USD","LU0070302665.USD","IE000M9KFDE8.USD","LU2125909593.SGD","LU1066051811.HKD","LU1720050803.USD","LU0417516738.SGD","SG9999001176.SGD","IE00BLSP4239.USD","LU1066053197.SGD","LU1699723380.USD","LU0689626769.HKD","IE0009355771.USD","LU0348766576.USD","IE00B1BXHZ80.USD","LU0965509010.AUD","LU1585245621.USD","SG9999002232.USD","IE00B5MMRT66.SGD","LU0203347892.USD","LU2112291526.USD","LU2125154935.USD","LU0868494708.USD","LU1035773651.USD","LU0648001328.SGD","LU1057294990.SGD","LU0348767384.USD","LU1032466523.USD","LU2106854487.HKD","LU0211331839.USD","LU0511384066.AUD","LU0058720904.USD","LU0289961442.SGD","LU1934455277.USD","LU1023059063.AUD","HRTS","BK4007","FHLC","SG9999014575.USD","LU1093756168.USD","LU2125909247.SGD","MRK","LU0985320562.USD","LU2491049909.HKD","LU0069063385.USD","SG9999015358.SGD","TRUH","LU0861579265.USD","LU1941712348.USD","LU1066051498.USD","LU0965508806.USD","SG9999014542.SGD","LU1989771016.USD","SG9999013999.USD","VHT","LU0348827113.USD","IE00BN8TJ469.HKD","LU1571399168.USD","BK4533","BK1161","LU2476274720.SGD","LU1989772840.SGD","LU2357627491.SGD","LU0122379950.USD","LU0124676726.USD","LU0477156953.USD","LU2468319806.SGD","LU2491050071.SGD","LU1093756325.SGD","SG9999014559.SGD","LU0417516902.SGD","LU1929549753.HKD","BK4559","SG9999015341.SGD","LU0289739699.SGD","LU0965509283.SGD","LU1983299246.USD","LU0561508036.HKD","LU1430594728.SGD","LU2399975544.HKD","LU0130517989.USD","LU0348825331.USD","PAWZ","LU0859254822.USD","LU2023250843.SGD","LU2361044949.HKD","LU2476274308.USD","LU1116320901.HKD","IE00BJT1NW94.SGD","LU2361044865.SGD","SG9999002224.SGD","LU1037948541.HKD","XLV","LU1162221912.USD","09926","LU0472753341.HKD","BK1574","BK4534","LU0942090050.USD","SG9999001176.USD","GDOC","LU0265550946.USD","BK4516","LU1291159041.SGD","LU1037948897.HKD","LU1066051225.USD","LU0130102774.USD","LU0320765489.SGD","IE00B543WZ88.USD","LU0265550359.USD","IYH","LU1201861249.SGD","LU0238689110.USD","LU0208291251.USD","LU1941712264.USD","LU0348735423.USD","SGXZ57979304.SGD","LU1961090484.USD","LU1069347547.HKD","LU1989772923.USD","LU0540923850.HKD","LU1934455863.HKD","LU0320765646.SGD","LU0289739343.SGD","LU0057025933.USD","PPH","LU0348783233.USD","FTXH","IE00BPRC5H50.USD","LU0266013472.USD","BK4550","LU0868494617.USD","LU2433249047.HKD","JDOC","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0823416689.USD","LU1923622614.USD","IE00BJJMRZ35.SGD","LU2360032135.SGD","LU0348784397.USD","LU0432979614.USD","LU2491050154.USD","BK4585","LU0006306889.USD","IHE","LU2324357040.USD","LU0965509101.SGD","LU2778985437.USD","SG9999014567.USD","LU0234572021.USD","LU1934455194.USD","IE0002141913.USD","IE00BLSP4452.SGD","BMED","LU1794554557.SGD","LU0980610538.SGD","LU0203345920.USD","LU0106261372.USD","RXL","LU0098860793.USD","LU2361045086.USD","IXJ","IE00B2B36J28.USD","LU0634319403.HKD","LU1116320737.USD","LU2461242641.AUD","SG9999001440.SGD","LU2089984988.USD","LU1974910355.USD","LU0417516571.SGD","LU2125154778.USD","IE00BBT3K403.USD","LU1061106388.HKD","LU2023250504.SGD","BK4588","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697046","title":"富瑞：康方生物(09926)依沃西单抗H-2研究取得正面结果 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697046","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667697046?lang=zh_cn&edition=full","pubTime":"2026-09-15 09:34","pubTimestamp":1789436076,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，富瑞发布研报称，康方生物(09926)依沃西单抗(Ivonescimab)H-2研究取得正面结果，数据显示，其中期总生存期(OS)具有统计学显著性，单药一线治疗PD-L1阳性非小细胞肺癌较帕博利珠单抗(Pembrolizumab)显著延长OS。该行认为，依沃西单抗拥有总生存期优势，数据令人鼓舞，维持康方生物“买入”评级及目标价226港元。数据显示，依沃西单抗组中位OS为30.8个月，风险比为0.73，中位随访36个月；帕博利珠单抗组中位OS为22.6个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655836","title":"资金动向｜北水抢筹智谱超12亿港元，连续10日抛售中芯国际","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655836","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667655836?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:46","pubTimestamp":1789386393,"startTime":"0","endTime":"0","summary":"跟踪南向资金最新动态","market":"hk","thumbnail":"https://img3.gelonghui.com/c8e01-ae165ef2-7e6f-406a-8eb6-bfcf9b66d370.jpg?guru_height=853&guru_width=1280&guru_size=107334","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c8e01-ae165ef2-7e6f-406a-8eb6-bfcf9b66d370.jpg?guru_height=853&guru_width=1280&guru_size=107334"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6645490","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0197773160.USD","BK1506","IE0003795394.USD","LU0823413660.USD","LU0052750758.USD","LU2778985437.USD","SGXZ31699556.SGD","LU0873338254.USD","SG9999015986.USD","LU0463099449.HKD","LU2226246903.HKD","SG9999018857.SGD","LU1883866441.USD","LU0315179316.USD","LU1691799644.USD","IE00BQXX3C00.GBP","LU0823426480.USD","LU0918141887.USD","LU2177674079.SGD","LU0210526637.USD","IE00B031HW06.USD","LU2023250504.SGD","BK1163","LU0329678170.USD","LU0345769128.USD","LU1810669033.SGD","LU1868837722.USD","BK1517","BK1142","LU0261947096.USD","LU0197773673.USD","LU2237443549.SGD","LU2237443622.USD","HK0000288784.HKD","LU2237443978.SGD","LU0791591158.USD","LU0043850808.USD","LU0878005551.USD","LU0264606111.USD","LU2097828557.USD","LU2265009873.SGD","LU0577902611.USD","LU2125910500.SGD","ESPO","ODDS","LU0080751232.USD","LU0231483743.USD","LU1951186391.HKD","LU0128525689.USD","LU0106252389.USD","SG9999001689.USD","LU0823397103.USD","00992","LU0269904917.USD","LU0096374516.USD","BK1249","IE00B0169L03.USD","LU2498475776.HKD","SG9999001093.SGD","BK1526","LU0149534421.HKD","LU0823397285.USD","LU0878004406.USD","LU0543330566.HKD","LU1769817096.USD","LU1974910355.USD","LU1102505929.USD","LU0501845795.SGD","LU0572944931.SGD","IE0032431581.USD","LU0633140560.USD","LU2051468812.USD","LU1044875133.USD","HBBD.SI","LU0287142896.SGD","LU0320764755.SGD","LU0531970944.HKD","LU0211331839.USD","LU0499858438.USD","LU1064130708.USD","LU1226287875.USD","LU1718418525.SGD","LU1568876335.HKD","LU0862451837.USD","LU0051755006.USD","LU0648948544.HKD","LU0289960550.SGD","LU0880133367.SGD","LU1960683339.HKD","LU0456846285.SGD","LU2133065610.SGD","IE00BMPRXR70.SGD","LU0577902454.USD","LU0211977185.USD","LU0449515922.USD","AAXJ","BK1610","LU1044874839.SGD","LU1804176565.USD","LU2087589342.USD","HK0000914660.USD","LU1282648689.USD","LU0786609619.USD","LU0203347892.USD","LU0244354667.USD","LU0516423174.USD","LNVGY","LU0414403682.SGD","00100","LU0049853897.USD","SG9999002463.SGD","LU0164865239.USD","HK0000107257.USD","LU0128522744.USD","LU0762542818.HKD","LU0737861772.HKD","LU0831093199.SGD","LU0251144936.SGD","LU2251237488.HKD","BABA","LU1196710351.USD","BK1608","LU0541502299.USD","LU0049112450.USD","LU2279701549.SGD","LU0192582467.USD","LDEM","IE00BGV7N243.SGD","LU1481107354.HKD","LU1981816686.USD","LU0326948709.USD","LU0254981946.USD","SGXZ51526630.SGD","LU0029875118.USD","LU0106959298.USD","LU0531971595.HKD","00981","LU0345776255.USD","IE00B543WZ88.USD","LU3063872942.SGD","LU0348784397.USD","LU0455707207.USD","GB00BDT5M118.USD","LU0259732245.USD","LU1152091754.HKD","LU1196710195.USD","LU1328615791.USD","LU2462611646.USD","LU0791590937.USD","LU1282651121.HKD","LU0588545490.SGD","LU0819123356.HKD","LU1226288170.HKD","LU1688375341.USD","LU0516422952.EUR","SG9999000327.SGD","LU1961090484.USD","LU3227948356.SGD","00700","IE00BZ08YS42.EUR","LU0572939691.SGD","IE00BZ08YR35.GBP","LU0188438112.USD","SGXZ62798434.SGD","LU0054450605.USD","KURE","LU2039709279.SGD","LU0052756011.USD","LU2045819591.USD","LU0502904849.HKD","LU0640798160.USD","LU0261950983.USD","LU1224709979.USD","LU0054237671.USD","LU2399975544.HKD","LU1235295612.USD","LU2008162690.USD","LU0823039010.USD","LU0477156797.USD","LU2237443382.USD","SG9999014674.SGD","LU0634319403.HKD","EEMX","LU0169518387.USD","LU1917777945.USD","LU0871576103.HKD","LU0072462343.USD","LU0594300179.USD","IE00BQXX3D17.EUR","IE00B031HY20.USD","LU2097828714.EUR","LU1439103000.SGD","LU0516422440.USD","LU0607220059.USD","LU1323998911.USD","LU0084288322.USD","BK1193","LU1504937902.USD","BIDD","LU0605514214.HKD","LU2152927971.USD","IE0008369823.USD","LU0345769631.USD","HK0000286598.CNH","BK1149","LU0985320562.USD","LU0181495838.USD","LU0630378692.HKD","LU1785774172.SGD","LU2237443895.HKD","LU0345775950.USD","LU0819121731.USD","LU0314109678.HKD","LU0384037296.USD","LU0708995153.HKD","SG9999001051.SGD","BK1591","09988","LU1725190679.HKD","LU1282651048.USD","LU0307460666.USD","LU1675838814.USD","LU2476274308.USD","SG9999014914.USD","LU0499858602.USD","LU0577902298.EUR","IE0003895053.USD","LU0029874905.USD","LU1720051017.SGD","HK0000306685.HKD","LU0651947912.USD","JADE","LU0348783233.USD","LU0456842615.SGD","LU2251237306.USD","IE00B5MMRT66.SGD","LU0594300419.USD","LU1044876610.USD","688981","IE00BMPRXN33.USD","IE0008368742.USD","LU0589944569.HKD","BK1607","HK0000320223.HKD","LU0348766576.USD","LU1733274473.HKD","SG9999001226.SGD","LU0890818403.SGD","LU0130103400.USD","LU0127658192.USD","SG9999017495.SGD","LU1048484197.HKD","TCEHY","LU0229945570.USD","LU0882747503.HKD","HK0000320264.USD","HK0000151867.HKD","LU0348805143.USD","LU0396098781.USD","LU1439102457.SGD","LU0143863784.USD","02513","LU1880383440.USD","HK0001040168.HKD","BK1618","LU1008478684.HKD","LU1211504680.USD","FFEM","BK1588","LU1201861165.SGD","SG9999018865.SGD","LU0700851271.USD","SG9999000459.SGD","LU0441854154.USD","GAMR","LU1328277881.USD","LU2293587155.HKD","LU0488056044.USD","SG9999001069.SGD","LU0348767384.USD","LU0143863198.USD","SG9999014880.SGD","LU0359202008.SGD","HK0000352382.USD","LU2449936058.SGD","IE0001KFT4U8.USD","LU2357305700.SGD","LU0449509016.USD","LU0348735423.USD","LU2106854487.HKD","LU0329678337.USD","IE00BZ08YT58.USD","LU1048596156.SGD","IE00B8HQ1Z84.USD","IE0034224299.USD","06869","BK1502","IE00B29SXG58.USD","LU0516422366.SGD","LU1046422090.SGD","LU1568876251.USD","LU1769817179.HKD","SG9999000418.SGD","LU0235996351.USD","LU0072913022.USD","LU0738912210.USD","CXSE","FDNI","LU0831103253.SGD","LU0456827905.SGD","BK1614","SGXZ81514606.USD","LU0633140727.USD","LU0117844026.USD","LU1282649810.SGD","LU0061477393.USD","89988","IE00BQXX3F31.USD","LU0117841782.USD","LU0417516738.SGD","LU0541501648.USD","LU1171460220.USD","SGXZ86797644.SGD","LU1048588211.SGD","LU0228367735.SGD","LU0348723411.USD","LU1267930227.SGD","LU0370786039.SGD","ALBmain","LU0979878070.USD","LU1642822792.SGD","LU1770036033.HKD","LU1023057109.AUD","LU0417516902.SGD","LU0132412106.USD","LU2317271919.USD","LU0642271901.SGD","HK0001040143.USD","LU0130518102.USD","BK1589","LU0648000940.SGD","IE00BPRC5H50.USD","IE0032834883.USD","LU0708995583.HKD","LU1813983027.USD","SG9999002562.SGD","LU1770034418.SGD","LU2488822045.USD","LU1224444064.USD","IE0009570106.USD","LU0348783662.USD","SG9999015978.USD","LU0672654166.SGD","LU1868838027.USD","IE0008368411.USD","LU1303224171.USD","LU0593848301.USD","LU2237443465.HKD","LU0327786744.USD","LU0128522157.USD","LU1242518931.SGD","TCHmain","LU0070217475.USD","KWEB","601869","LU2097829019.USD","80992","TCHI","LU0516423091.SGD","HK0000352291.HKD","LU1807302812.USD","LU0107464264.USD","LU1105468828.SGD","IE00BF5LJ272.USD","LU0039217434.USD","LU0828238088.HKD","LU1366334651.USD","BK1117","LU2294711473.HKD","LU0203345920.USD","LU1831875114.USD","LU2242644610.SGD","BK1586","BK1584","LU1629966141.USD","LU1808992512.USD","LU1102505762.USD","IE00B97KM107.HKD","LU1282649067.USD","LU1733274390.USD","LU1115378108.SGD","LU0611395673.USD","LU1282649141.HKD","JEMA","LU0067412154.USD","LU0469268626.HKD","IE0003851619.USD","LU1188198961.HKD","SOCL","LU0588545730.USD","LU1064131003.USD","IE0031814852.USD","BK1574","LU0823038988.USD","BK1095","IE00B8L5B284.USD","IE00B067MR52.USD","LU0164872284.USD","LU0886674414.USD","EMC","LU0431992006.USD","LU0683595622.HKD","LU0163747925.USD","LU1316542783.SGD","LU1515016050.SGD","LU0762541174.USD","LU0210527791.USD","LU0572940350.SGD","SGXZ90724238.SGD","LU0310800965.SGD","LU0164880469.USD","LU0417516571.SGD","BK1531","LU1720050803.USD","LU1226287529.USD","SG9999001846.SGD","LU1956131251.USD","SG9999007991.SGD","LU1051768304.USD","LU1226288253.USD","LU1242518857.USD","SG9999003461.SGD","SG9999014898.SGD","LU0898667661.SGD","LU0320764599.SGD","LU2279858448.HKD","LU0540923850.HKD","LU0173614495.USD","LU2476274720.SGD","LU0608807433.USD","LU0856984785.SGD","LU0048388663.USD","LU0918141705.HKD","SG9999015952.SGD","LU1719994722.HKD","LU1548497426.USD","LU0348788117.USD","LU0348816934.USD","LU0577902538.SGD","SG9999001903.USD","LU0862451753.SGD","HTCD.SI","LU2097828631.EUR","LU1206782309.USD","LU0210533765.USD","LU0359201612.USD","BK1501","BK1523","IE00B0169N27.USD","IE00B3M56506.USD","LU0214875030.USD","LU0175139822.USD","LU1226287792.SGD","IE0008368304.USD","BK1516","LU0630378429.USD","LU1196710864.SGD","LU0011963245.USD","LU0293314216.USD","BKF","HK0000288743.USD","LU0543330483.HKD","LU0972618739.USD","SG9999014906.USD","LU0509642566.USD","LU0577902371.SGD","LU2362541513.USD","LU2257852520.SGD","LU1993786604.SGD","LU0823041008.USD","HK0000306701.USD","LU1868837565.USD","LU0326950275.SGD","LU1720051108.HKD","LU0359201885.HKD","LU2362541273.HKD","LU0348825331.USD","LU0348814723.USD","SG9999013353.USD","LU0784639295.USD","LU0588545904.SGD","LU0828237940.HKD","LU0196878994.USD","BK1615","LU0047713382.USD","LU0762540952.USD","IE00B031J352.USD","LU2125910849.SGD","09926","LU0348827113.USD","SG9999006514.SGD","LU1152091168.USD","LU0315178854.USD","LU2097828805.USD","LU0823040885.USD","LU0106259558.USD","LU1880398471.USD","BK1575","BK1521","LU1366334578.USD","LU0828237510.HKD","LU0048597586.USD","LU0608807946.USD","HK0000914686.HKD","SG9999006597.SGD","IE00B0JY6N72.USD","LU1734074674.USD","BK1609","LU0865486749.SGD","SG9999002828.SGD","LU0797268264.HKD","LU0868486357.SGD","LU0651946864.USD","LU0737861699.HKD","LU0165289439.USD","BK1161","LU0149721374.USD","LU1051769294.HKD","LU0561508036.HKD","SG9999004220.SGD","LU0320764243.SGD","LU1880398554.USD","LU1880383366.USD","LU0588546209.SGD","EMCS","XSOE","LU1655091459.SGD","LU0650527681.SGD","LU0675040207.SGD","LU2362540622.SGD","LU2097828474.EUR","SG9999015945.SGD","LU0228659784.USD","LU1814569148.SGD","LU2148510915.USD","LU0821914370.USD","LU0823413587.USD","LU1226288097.SGD","SGXZ99366536.SGD","LU2247934214.USD","LU1251922891.USD","LU0140636845.USD","LU1794554557.SGD","LU0823426308.USD","LU0048580855.USD","LU0328353924.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656624","title":"大行评级丨杰富瑞：康方生物依沃西单抗H-2研究取得正面结果，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656624","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667656624?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:59","pubTimestamp":1789372758,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0348766576.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348784397.USD","LU0348783233.USD","LU0348767384.USD","LU1720050803.USD","LU0348735423.USD","BK1161","BK1574","LU2488822045.USD","LU2476274720.SGD","LU0348825331.USD","LU0561508036.HKD","LU0417516571.SGD","LU0540923850.HKD","LU0634319403.HKD","KURE","LU2476274308.USD","LU0417516738.SGD","09926","LU0417516902.SGD","LU2399975544.HKD","LU0348827113.USD","IE00B543WZ88.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667085656","title":"小摩：康方生物(09926)HARMONi-2总生存期数据强劲 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667085656","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667085656?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:38","pubTimestamp":1789371481,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，康方生物公布HARMONi-2总生存期数据更新，其整体OS数据相当强劲，风险比为0.73，置信区间0.57至0.95，p值0.009。该行认为，HARMONi-2的OS数据更新将对两项全球三期试验产生正面启示，分别为HARMONi-3的鳞状细胞队列及HARMONi-7。研报亦厘清HARMONi-2统计计划的若干事项，包括目前WCLC数据为第二次计划中期分析的结果。截至2026年8月20日数据截止日，中位随访时间约36个月，发生234宗OS事件，单侧alpha为0.0141。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"小摩：康方生物(09926)HARMONi-2总生存期数据强劲 维持“增持”评级","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667559216","title":"花旗：康方生物(09926)HARMONi-2总生存期优效强化ivonescimab差异化优势 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667559216","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667559216?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:19","pubTimestamp":1789370340,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，康方生物的HARMONi-2中期读数显示，ivonescimab作为PD-L1阳性非小细胞肺癌一线单药治疗，对比pembrolizumab展现有意义的总生存期优效，强化其差异化定位，全球读数仍是关键。该行维持康方生物“买入”评级，目标价171港元不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股异动 | 创新药概念股全线走高 WCLC临床数据重磅催化 机构指回调后配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667608630?lang=zh_cn&edition=full","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","LU0455707207.USD","IE00B543WZ88.USD","IBBQ","BK1589","KURE","LU2476274720.SGD","LU0348767384.USD","LU2476274308.USD","01177","LU0244354667.USD","BK1191","LNGR","LU0348735423.USD","LU0348766576.USD","LU0417516738.SGD","MEDX","159992","LU0348827113.USD","HK0000165453.HKD","LU2488822045.USD","VXUS","LU1961090484.USD","LU2097828557.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348825331.USD","01530","KCAI","LU2778985437.USD","06978","BK1593","LU0607220059.USD","09926","LU1969619763.USD","LU0634319403.HKD","LU2097828805.USD","LU0326950275.SGD","LU1188198961.HKD","BK1574","BK1521","LU0561508036.HKD","BK4588","IE00BZ08YR35.GBP","01801","LU0348784397.USD","LU2097828714.EUR","BK1161","LU1831875114.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637732","title":"大行评级丨花旗：维持康方生物“买入”评级，HARMONi-2总生存期优效强化ivonescimab差异化优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637732","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667637732?lang=zh_cn&edition=full","pubTime":"2026-09-14 13:24","pubTimestamp":1789363448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2476274308.USD","LU1794554557.SGD","LU0348767384.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU1961090484.USD","BK1574","LU2488822045.USD","LU0348783233.USD","LU2399975544.HKD","LU0348766576.USD","LU0540923850.HKD","LU0348827113.USD","IE00B5MMRT66.SGD","LU0417516902.SGD","09926","LU2476274720.SGD","KURE","LU0348825331.USD","LU0348784397.USD","LU0417516738.SGD","LU1720050803.USD","LU2778985437.USD","LU0348735423.USD","LU0417516571.SGD","LU0561508036.HKD","BK1161","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632842","title":"港股异动丨康方生物涨近7%，依沃西试验生存期超过默沙东竞品","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632842","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667632842?lang=zh_cn&edition=full","pubTime":"2026-09-14 11:33","pubTimestamp":1789356838,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2778985437.USD","BK1574","LU0348735423.USD","KURE","LU0417516571.SGD","LU0417516738.SGD","LU0348825331.USD","LU2476274308.USD","LU0348783233.USD","LU0561508036.HKD","LU0348784397.USD","LU0417516902.SGD","LU2488822045.USD","09926","BK1161","LU0634319403.HKD","LU2399975544.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0348827113.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU1720050803.USD","LU1794554557.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667463107","title":"康方生物港股走高 其依沃西单药在试验中的总生存期超过默沙东竞品","url":"https://stock-news.laohu8.com/highlight/detail?id=2667463107","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667463107?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:16","pubTimestamp":1789352160,"startTime":"0","endTime":"0","summary":"南方财经9月14日电，康方生物港股盘初一度上涨5.8%，随后收窄涨幅。此前公司宣布，对比默沙东公司的帕博利珠单抗，其肿瘤免疫药物依沃西显著延长了中位总生存期(OS)至30.8个月，而前者为22.6个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873200884.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873200884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348735423.USD","LU0348767384.USD","LU2476274720.SGD","LU2476274308.USD","BK1161","LU0561508036.HKD","LU1794554557.SGD","KURE","LU1961090484.USD","LU0348784397.USD","LU0348766576.USD","BK1574","LU2399975544.HKD","IE00B543WZ88.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348783233.USD","LU2488822045.USD","LU2778985437.USD","VXUS","LU1720050803.USD","IE00BPRC5H50.USD","BK4588","LU0417516571.SGD","KCAI","LU0348825331.USD","LU0540923850.HKD","LU0417516902.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","09926","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631397","title":"康方生物盘初涨逾4% 依沃西对比帕博利珠单抗相关研究成果于WCLC大会重磅发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631397","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667631397?lang=zh_cn&edition=full","pubTime":"2026-09-14 09:44","pubTimestamp":1789350240,"startTime":"0","endTime":"0","summary":"据康方生物官微消息，在国际肺癌研究协会主办的2026年世界肺癌大会上，公司全球首创肿瘤免疫2.0基石药物依沃西，对比帕博利珠单抗，一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的随机、双盲、对照、多中心、注册性III期临床研究的OS显著阳性结果重磅发布。截至目前，依沃西在多项头对头对比PD-1/L1疗法的III期临床中取得OS和PFS双阳性结果，并逐步拓展至肺癌以外的重大实体瘤领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-14/doc-iniruara9666421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09926","LU0348767384.USD","LU1720050803.USD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0348766576.USD","LU1961090484.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348783233.USD","LU2476274720.SGD","LU2488822045.USD","LU0634319403.HKD","LU0417516738.SGD","LU0417516571.SGD","LU2476274308.USD","LU2399975544.HKD","LU0540923850.HKD","LU0348825331.USD","LU0348784397.USD","LU0348827113.USD","LU0417516902.SGD","KURE","IE00BPRC5H50.USD","BK1574","LU1794554557.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183800015","title":"异动解读｜康方生物开盘上涨3.65%，依沃西HARMONi-2研究OS数据在WCLC重磅发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1183800015","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183800015?lang=zh_cn&edition=full","pubTime":"2026-09-14 09:31","pubTimestamp":1789349463,"startTime":"0","endTime":"0","summary":"9月14日，康方生物开盘上涨3.65%，报93.75港元/股，成交额1714.9万港元。消息面上，9月13日，在国际肺癌研究协会主办的世界肺癌大会上，康方生物核心产品依沃西对比帕博利珠单抗（K药）一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床研究HARMONi-2的OS显著阳性结果正式发布，该研究成果作为Late-Breaking Abstract被大会选为口头报告，并入选官方新闻发布计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物上涨，依沃西OS数据重磅发布","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667639745","title":"港股异动 | 康方生物(09926.HK)高开逾4% 依沃西对比帕博利珠单抗相关研究成果于WCLC大会重磅发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667639745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667639745?lang=zh_cn&edition=full","pubTime":"2026-09-14 09:28","pubTimestamp":1789349287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2399975544.HKD","LU0417516738.SGD","LU0348783233.USD","LU1794554557.SGD","LU0348766576.USD","LU2476274720.SGD","LU0634319403.HKD","LU1961090484.USD","09926","LU0348784397.USD","KURE","LU2488822045.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0417516571.SGD","IE00B543WZ88.USD","BK1161","LU0348825331.USD","LU0540923850.HKD","LU0561508036.HKD","LU1720050803.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU0417516902.SGD","BK1574","LU0348827113.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188195029","title":"异动解读｜康方生物盘中下跌3.21%，报90.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188195029","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188195029?lang=zh_cn&edition=full","pubTime":"2026-09-11 10:37","pubTimestamp":1789094256,"startTime":"0","endTime":"0","summary":"9月11日，康方生物盘中下跌3.21%，报90.6港元/股，成交额3.06亿港元。康方生物所在的生物科技行业中，个股普遍走弱，其中信达生物跌2.07%，百济神州跌1.64%，剂泰科技-P跌11.9%，云顶新耀跌4.9%，三生制药跌1.54%。康方生物科技是一家致力于研究、开发、生产及商业化抗体药的投资控股公司，在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域，核心产品包括卡度尼利（PD-1/CTLA-4）、依沃西（PD-1/VEGF）等创新双特异性抗体药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU2580892862.HKD","LU1226287792.SGD","09926","600030","06160","BK0028","01801","09688","LU0561508036.HKD","SG9999004220.SGD","02616","LU1813983027.USD","LU1226287875.USD","LU1255011170.USD","LU1880383366.USD","01177","LU1655091616.SGD","KCE","KURE","LU1720050803.USD","LU0417516738.SGD","LU1997245177.USD","LU0572944931.SGD","02142","09995","LU0348783233.USD","02269","LU1794554557.SGD","LU1961090484.USD","01093","LU0405327494.USD","06030","01877","IE00B543WZ88.USD","LU0348825331.USD","LU1580142542.USD","LU1969619763.USD","LU2039709279.SGD","BK1161","BK1141","06185","LU0979878070.USD","LU1820825898.SGD","LU0516422952.EUR","LU0463099449.HKD","LU0819121731.USD","LU0181495838.USD","LU1064130708.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187434134","title":"异动解读｜康方生物盘中下跌3.06%，报98.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187434134","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187434134?lang=zh_cn&edition=full","pubTime":"2026-09-07 10:59","pubTimestamp":1788749981,"startTime":"0","endTime":"0","summary":"9月7日，康方生物盘中下跌3.06%，报98.1港元/股，成交额4.8亿港元。康方生物所在的生物科技行业中，个股中，信达生物跌0.78%，和铂医药-B跌1.63%，百济神州跌2.72%，剂泰科技-P涨8.54%，基石药业-B跌4.04%。康方生物科技是一家致力于研究、开发、生产及商业化抗体药的投资控股公司，在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域，核心产品包括卡度尼利（PD-1/CTLA-4）、依沃西（PD-1/VEGF）等创新双特异性抗体药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0304},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0366},{"period":"6month","weight":-0.215},{"period":"1year","weight":-0.2965},{"period":"ytd","weight":-0.1969}],"compareEarnings":[{"period":"1week","weight":-0.014},{"period":"1month","weight":-0.034},{"period":"3month","weight":0.0284},{"period":"6month","weight":-0.0266},{"period":"1year","weight":-0.0856},{"period":"ytd","weight":-0.04}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.012805},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032387},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}